Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-11-06 Sale |
2024-11-08 4:53 pm |
Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director |
6,700 | $36.76 | $246,313 | 27,360 (Indirect) |
View |
| 2024-10-25 Sale |
2024-10-28 4:41 pm |
Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director |
300 | $36.43 | $10,929 | 34,060 (Indirect) |
View |
| 2024-09-03 Sale |
2024-09-05 4:04 pm |
Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer |
18,531 | $28.17 | $522,074 | 116,422 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-15 Option Award |
2025-01-17 4:36 pm |
N/A 2035-01-15 |
Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer |
95,500 | $0 | 95,500 (Direct) |
View |
| 2025-01-15 Option Award |
2025-01-17 4:36 pm |
N/A 2035-01-15 |
Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer |
95,500 | $0 | 95,500 (Direct) |
View |
| 2025-01-15 Option Award |
2025-01-17 4:35 pm |
N/A 2035-01-15 |
Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer |
370,000 | $0 | 370,000 (Direct) |
View |
| 2025-01-15 Option Award |
2025-01-17 4:34 pm |
N/A 2035-01-15 |
Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks |
95,500 | $0 | 95,500 (Direct) |
View |
| 2025-01-10 Other |
2025-01-14 5:16 pm |
N/A N/A |
Spyre Therapeutics Inc. | SYRE | HENDERSON MICHAEL THOMAS Director |
105,379 | $0 | 210,758 (Direct) |
View |
| 2024-10-01 Option Award |
2024-10-01 6:34 pm |
N/A 2034-10-01 |
Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer |
400,000 | $0 | 400,000 (Direct) |
View |
| 2024-05-14 Option Award |
2024-05-16 4:10 pm |
N/A 2034-05-14 |
Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director |
22,646 | $0 | 22,646 (Indirect) |
View |
| 2024-05-14 Option Award |
2024-05-16 4:10 pm |
N/A 2034-05-14 |
Spyre Therapeutics Inc. | SYRE | Milligan Sandra Director |
21,980 | $0 | 21,980 (Direct) |
View |
| 2024-05-14 Option Award |
2024-05-16 4:10 pm |
N/A 2034-05-14 |
Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director |
11,323 | $0 | 11,323 (Direct) |
View |
| 2024-05-14 Option Award |
2024-05-16 4:10 pm |
N/A 2034-05-14 |
Spyre Therapeutics Inc. | SYRE | Stelzer Laurie Director |
11,323 | $0 | 11,323 (Direct) |
View |
| 2024-05-14 Option Award |
2024-05-16 4:10 pm |
N/A 2034-05-14 |
Spyre Therapeutics Inc. | SYRE | HENDERSON MICHAEL THOMAS Director |
11,323 | $0 | 11,323 (Direct) |
View |
| 2024-04-25 Exercise |
2024-04-25 4:55 pm |
N/A N/A |
Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director |
3,730,672 | $0 | 5,176,222 (Indirect) |
View |
| 2024-02-15 Option Award |
2024-02-20 9:21 pm |
N/A N/A |
Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer |
400 | $9.82 | 746,907 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-05 5:29 pm |
N/A 2034-02-01 |
Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director |
40,000 | $0 | 40,000 (Direct) |
View |
Ownership |
2024-02-05 5:25 pm |
N/A 2033-11-22 |
Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director |
0 | $0 | 477,000 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-02 8:31 pm |
N/A 2034-02-01 |
Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer |
277,750 | $0 | 277,750 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-02 8:27 pm |
N/A 2034-02-01 |
Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer |
70,000 | $0 | 70,000 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-02 8:23 pm |
N/A 2034-02-01 |
Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks |
63,000 | $0 | 63,000 (Direct) |
View |
| 2023-12-29 Other |
2023-12-29 5:00 pm |
N/A N/A |
Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner |
3,841,518 | $0 | 5,485,719 (Indirect) |
View |
| 2023-12-22 Option Award |
2023-12-22 6:00 pm |
N/A N/A |
Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer |
134,953 | $0 | 134,953 (Direct) |
View |
| 2023-12-07 Option Award |
2023-12-11 5:41 pm |
N/A N/A |
Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner |
16,667 | $600 | 16,667 (Indirect) |
View |
| 2023-11-22 Option Award(A) |
2023-12-08 4:07 pm |
N/A 2033-11-22 |
Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director |
50,000 | $0 | 84,360 (Direct) |
View |
| 2023-11-24 Conversion(A) |
2023-12-08 4:07 pm |
N/A N/A |
Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director |
35,219 | $0 | 84,360 (Indirect) |
View |
Ownership(A) |
2023-12-08 4:03 pm |
N/A N/A |
Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director |
0 | $0 | 34,360 (Indirect) |
View |
| 2023-11-24 Conversion |
2023-11-28 4:05 pm |
N/A N/A |
Spyre Therapeutics Inc. | AGLE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner |
3,521,367 | $0 | 4,250,938 (Indirect) |
View |
| 2023-11-22 Option Award |
2023-11-27 4:36 pm |
N/A 2033-11-22 |
Spyre Therapeutics Inc. | AGLE | Albers Jeffrey W. Director |
50,000 | $0 | 50,000 (Direct) |
View |
| 2023-11-22 Option Award |
2023-11-27 4:33 pm |
N/A 2033-11-22 |
Spyre Therapeutics Inc. | AGLE | Stelzer Laurie Director |
50,000 | $0 | 50,000 (Direct) |
View |
| 2023-11-22 Option Award |
2023-11-27 4:25 pm |
N/A 2033-11-22 |
Spyre Therapeutics Inc. | AGLE | Turtle Cameron Chief Executive Officer |
374,000 | $0 | 1,120,507 (Direct) |
View |
| 2023-11-24 Conversion |
2023-11-27 4:25 pm |
N/A N/A |
Spyre Therapeutics Inc. | AGLE | Turtle Cameron Chief Executive Officer |
741,526 | $0 | 1,120,507 (Direct) |
View |
| 2023-09-01 Option Award |
2023-09-05 4:15 pm |
N/A 2033-09-01 |
Aeglea BioTherapeutics Inc. | AGLE | King-Jones Heidy See Remarks |
13,495,255 | $0 | 13,495,255 (Direct) |
View |
| 2023-09-01 Option Award |
2023-09-05 4:10 pm |
N/A 2033-09-01 |
Aeglea BioTherapeutics Inc. | AGLE | Burrows Scott L Chief Financial Officer |
10,121,441 | $0 | 10,121,441 (Direct) |
View |
Ownership |
2023-06-30 5:32 pm |
N/A N/A |
Aeglea BioTherapeutics Inc. | AGLE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner |
0 | $0 | 536,284,540 (Indirect) |
View |
Ownership |
2023-06-30 5:14 pm |
N/A N/A |
Aeglea BioTherapeutics Inc. | AGLE | Turtle Cameron Chief Operating Officer |
0 | $0 | 65,959,896 (Direct) |
View |